特利加压素治疗肝硬化合并肝癌术后腹腔积液的临床疗效观察

Teripressin for the treatment of postoperative ascites in cirrhotic liver cancer patients

目的分析特利加压素治疗肝硬化合并肝癌术后患者腹腔积液的临床疗效。方法90例患者分为实验组和对照组,实验组在常规治疗和利尿剂治疗基础上加用特利加压素治疗,对照组仅仅采用常规及利尿剂治疗。观察比较两组患者的治疗效果及术后恢复情况,并对其进行分析总结。结果(1)实验组术后尿量多于对照组,差异有统计学意义(F = 39 401.325,P = 0.000);术后腹腔积液量较术前明显增多(F = 265. 163,P = 0.000),且实验组多于对照组(F = 6. 470,P = 0. 044),(2)两组患者在围手术期血肌酹、尿素氮、血钠及血钾变化不明显,差异无统计学意义(P>0.05),(3)实验组和对照组的平均住院时间分别为(22. 2 ± 3. 1) d,(26. 6 ± 5. 1) d,差异有统计学意义(t =-4. 945,P =0.001)。结论特利加压素治疗肝硬化合并肝癌术后腹腔积液的临床疗效明显,且安全有效。

Objective To analyze the clinical efficacy of teripressin in the treatment of postoperative ascites in patients with cirrhosis and liver cancer. Method 90 patients were divided into experimental group treated with terlipressin on the basis of routine and diuretic treatment, and control group treated with routine and diuretics only. Result There was significant difference in urine volume between the two groups ( F = 39 401. 325, P = 0. 000). The amount of urine in the experimental group was more than that in the control group. The amount of peritoneal effusion significantly increased after operation ( F = 265. 163 , P =0. 000), and that in the experimental group was more than that in the control group ( F = 6. 470, P =0. 044). The levels of serum creatinine, urea nitrogen, sodium and blood in the two groups were higher than those in the control group ( F = 6. 470, P = 0. 044). The change of potassium was not obvious, and the difference was not statistically significant ( P > 0. 05 ). The average hospitalization time in the experimental group and the control group were ( 22. 2 ± 3. 1 ) d,( 26. 6 ± 5. 1 ) d respectively,( t =-4. 945 , P =0. 001 ). Conclusion Terlipressin is effective and safe in the treatment of peritoneal effusion after hepatic cirrhosis combined with hepatocellular carcinoma.